Gross-Goupil M - Search Results

1

Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.

Gross-Goupil M, François L, Quivy A, Ravaud A. Gross-Goupil M, et al. Clin Med Insights Oncol. 2013 Oct 29;7:269-77. doi: 10.4137/CMO.S10594. Clin Med Insights Oncol. 2013. PMID: 24250243 Free PMC article. Review.

2

Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.

Ravaud A, Grossgoupil M. Ravaud A, et al. Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7. Lancet Oncol. 2010. PMID: 20359658 No abstract available.

3

[mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].

Ravaud A, Bernhard JC, Gross-Goupil M, Digue L, Ferriere JM. Ravaud A, et al. Bull Cancer. 2010;97:45-51. doi: 10.1684/bdc.2010.1069. Bull Cancer. 2010. PMID: 20418203 Review. French.

4

[Bladder cancer and new drugs].

Massard C, Albouy B, Gross-Goupil M, Ravaud A. Massard C, et al. Bull Cancer. 2010;97 Suppl Cancer de la vessie:43-50. doi: 10.1684/bdc.2010.1100. Bull Cancer. 2010. PMID: 20534389 French.

5

Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.

Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A. Roubaud G, et al. Oncology. 2011;80(3-4):214-8. doi: 10.1159/000329078. Epub 2011 Jul 1. Oncology. 2011. PMID: 21720184

6

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.

Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H, Ravaud A. Roca S, et al. Acta Oncol. 2011 Oct;50(7):1135-6. doi: 10.3109/0284186X.2011.592149. Epub 2011 Jul 5. Acta Oncol. 2011. PMID: 21726178 No abstract available.

7

[Rationale for the local treatment of metastases].

Ravaud A, Roca S, Quivy A, Gross-Goupil M. Ravaud A, et al. J Radiol. 2011 Sep;92(9):821-4. doi: 10.1016/j.jradio.2011.07.006. Epub 2011 Sep 8. J Radiol. 2011. PMID: 21944241 French.

8

Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Gross-Goupil M, Massard C, Ravaud A. Gross-Goupil M, et al. Curr Urol Rep. 2012 Feb;13(1):16-23. doi: 10.1007/s11934-011-0232-y. Curr Urol Rep. 2012. PMID: 22139625 Review.

9

Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma.

Ravaud A, Gross-Goupil M. Ravaud A, et al. Cancer Treat Rev. 2012 Dec;38(8):996-1003. doi: 10.1016/j.ctrv.2012.01.003. Epub 2012 Feb 12. Cancer Treat Rev. 2012. PMID: 22330762 Review.

10

[Strategy in advanced castration-resistant prostate cancer].

Gross-Goupil M, Roca S, Pasticier G, Ravaud A. Gross-Goupil M, et al. Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562. Bull Cancer. 2012. PMID: 22522582 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters